MiR-223 or miR-126 predicts resistance to dual antiplatelet therapy in patients with ST-elevation myocardial infarction.

Abstract

OBJECTIVE:

To explore the role of miR-223 and miR-126 in predicting treatment responses to dual antiplatelet therapy (DAPT) in patients with ST-elevation myocardial infarction (STEMI).

METHODS:

Plasma miR-223 and miR-126 levels were measured before treatment. Treatment responses and 2-year survival were determined. In vitro experiments were performed to explore the mechanism of action.

RESULTS:

Patients with resistance to DAPT had a lower level of miR-223 and miR-126. Cardiac-event-free survival was shorter in patients with lower miR-223 or miR-126 levels. MiR-223 and miR-126 independently predicted DAPT resistance. Modulating miR-223 or miR-126 in platelets in vitro significantly changed the response to clopidogrel by regulating platelet aggregation.

CONCLUSION:

MiR-223 and miR-126 play a role in DAPT resistance and may provide potential biomarkers in patients with STEMI.

• Authors: Xiaojing Li, Qi Yao, Hanbin Cui, Jun Yang, Nan Wu, Yahui Liu, Ying Zhou, Yinwei Zhang, Jia Su, Yezi Xia, Xiaomin Chen
• Journal: The Journal of international medical research (J Int Med Res) Vol. 49 Issue 6 Pg. 3000605211016209 (Jun 2021) ISSN: 1473-2300 [Electronic] England
• PMID: 34098766 (Publication Type: Journal Article)

Chemical References

• MIRN126 microRNA, human
• MIRN223 microRNA, human
• MicroRNAs
• Platelet Aggregation Inhibitors
• Clopidogrel

Topics

• Blood Platelets
• Clopidogrel (therapeutic use)
• Humans
• MicroRNAs (genetics)
• Percutaneous Coronary Intervention
• Platelet Aggregation Inhibitors (therapeutic use)
• ST Elevation Myocardial Infarction (drug therapy, genetics)
• Treatment Outcome